Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool December 12, 2006 Dan Caplinger	Don't Fall Into the Doughnut Hole Medicare Part D provides valuable benefits for seniors. However, because the doughnut hole is a gap in coverage by prescription-drug plans, seniors must be prepared to deal with the costs associated with it.
The Motley Fool December 23, 2009 Brian Orelli	2009 Cheers and Jeers for Pharma Unfortunately, it was more of the latter.
The Motley Fool April 4, 2011 Selena Maranjian	This Expense Could Wipe You Out You probably already realize that a significant amount of your spending in retirement will go toward health care. But you may still be surprised when you see the actual average price tag.
The Motley Fool October 30, 2009 Brian Orelli	Come On -- They Represent Your Mom! A Republican fight with AARP proves that we're still seeing politics as usual.
The Motley Fool November 30, 2011 Brian Orelli	This $581 Doughnut Hole Costs Drugmakers It's costing drugmakers money. Can they recoup it elsewhere?
BusinessWeek May 1, 2006 Howard Gleckman	Medicare Surprise Why many seniors could temporarily lose drug coverage.
Managed Care December 2002	Drug-discount program's effectiveness hindered by lack of use California offers a prescription drug discount program that allows Medicare beneficiaries to get discounts just by showing their Medicare cards to pharmacists. Unfortunately, a majority of those eligible -- both those with and without drug coverage -- have never heard of the program.
The Motley Fool January 22, 2007 Dan Caplinger	Understanding Medicare: Benefits Medical coverage for seniors is a big part of a strong retirement-protection plan.
The Motley Fool February 25, 2010 Brian Orelli	An Untouched Market Waiting to Be Captured Unfilled prescriptions are a potential boon to drug companies.
The Motley Fool August 18, 2006 Dan Caplinger	The Medicare Drug Dilemma: Part 1 Seniors have a great benefit available to them, but it's tough sorting through it all. We're here to help.
The Motley Fool August 26, 2010 Brian Orelli	Drug Prices Up, but Don't Read Too Much Into It AARP is out with its annual report on the cost of medications, and it's more of the same: bad news if you're a consumer, but good news if you're invested in drugmakers.
Registered Rep. May 25, 2011 Mark Miller	Pros and Cons of the Healthcare Reform Law The new health reform law already is changing the health insurance market in important ways that will affect your clients' choices and expenses.
Managed Care December 2007	Insurers Offer More Coverage to Fill Part D Gap Filling the gap in coverage in which the enrollee pays 100% of total drug costs before catastrophic coverage begins will be a significant issue that stand-alone Prescription Drug Plans and Medicare Advantage Prescription Drug plans face in 2008.
The Motley Fool October 3, 2006 Brian Gorman	Britain's Psychiatric Stir-Up The U.S. government may be forced to follow Great Britain's example regarding drug reimbursements, given recent developments in Medicare. What will this mean for Big Pharma?
BusinessWeek October 3, 2005 Howard Gleckman	Medicare: Decisions, Decisions With drug and HMO plans now in the mix, seniors face a raft of complex choices.
The Motley Fool October 5, 2010 Andrew Bond	Wal-Mart Enters the Health-Care Fray Wal-Mart and Humana's partnership will have competitors scrambling.
The Motley Fool May 18, 2010 Brian Orelli	Price Inflation in Check? Not in This Industry. Drug prices are on the rise. For now.
The Motley Fool December 3, 2009 Brian Orelli	Health-Care Reform Is Very Taxing On the industries that keep us alive.
Registered Rep. October 13, 2011 Mark Miller	Determining Your Elderly Clients' Best-Fit in Medicare Plans You may be able to help senior clients save thousands of dollars in out-of-pocket health care costs by encouraging them to comparison shop for Medicare prescription drug and managed care options during the program's annual fall enrollment season.
Managed Care December 2006	Medicare Part D Recipients Plan to Stay with Coverage Seventy-three percent of people in Medicare Advantage prescription drug plans want to stick with their current coverage package in 2007, according to a Wall Street Journal/Harris Interactive poll.
The Motley Fool August 18, 2006 Dan Caplinger	The Medicare Drug Dilemma: Part 2 What happens when you need to make a change to your Medicare prescription plan? We'll help you figure it out.
BusinessWeek May 20, 2009 Maria Bartiromo	Pfizer's Kindler on Health-Care Reform and the Wyeth Deal Pfizer's CEO discusses its acquisition of Wyeth and its plan to provide some drugs for free to those without jobs and insurance.
The Motley Fool September 9, 2009 Brian Orelli	Don't Like High Drug Costs? Blame Canada. Through a combination of price controls instituted by the Patented Medicine Prices Review Board, and through government negotiations, Canada is able to keep its drug costs down for its citizens. But that doesn't make it right.
Managed Care March 2004	More Retirees Face Life Without Health Benefits Employer-sponsored health benefits for retirees could go the way of house calls and dial phones thanks to increasing health care costs. A study says that 10 percent of 408 companies with 1,000 employees or more plan to drop coverage for future retirees.
Financial Planning February 1, 2006 Janet Aschkenasy	Drug Deals Here is how to help your financial advisory clients make sense of Medicare Part D.
The Motley Fool January 26, 2007 Dan Caplinger	Fall Into the Medigap Unfortunately, choosing the best Medigap policy for your particular situation can be complicated. You have to analyze the various options included in the plans that are available to you.
Chemistry World March 25, 2010 Rebecca Trager	Big pharma scores in US healthcare reform President Obama has signed the biggest US healthcare reform since the 1960s, and although it is largely seen as a victory for the pharmaceutical industry, some analysts are characterising it as a 'double-edged sword'.
Managed Care October 2002	Though M+C Erosion Slows, Reimbursement Still an Issue The exodus of health plans from Medicare+Choice will moderate somewhat next year, offering hope that the struggling system can make a comeback.
The Motley Fool March 22, 2010 Brian Orelli	Health-Care Reform Passes! Here's Where to Invest Now Some healthy suggestions for your portfolio.
Financial Advisor March 2006 Karen DeMasters	Clients Lost In Medicare Lurch Although some of the more than 40 million eligible Medicare recipients in the nation already have signed up for the new prescription drug benefits program Part D, many people still are seeking the advice of financial planners and weighing the options that are available to them.
The Motley Fool January 28, 2010 Brian Orelli	Health-Care Reform Is Dead. Probably. Breaking up the bill doesn't seem like the answer. What do insurers and pharmaceutical companies have to say?
The Motley Fool February 10, 2010 Brian Orelli	Icahn's Smiling -- Should We Be? Biogen Idec's fourth quarter results must have made Carl Icahn smile. But the guidance for next year gives pause.
BusinessWeek December 15, 2003 Howard Gleckman	Medicare's $86 Billion Band-Aid The subsidy won't stop many companies from scaling back retiree drug benefits.
Managed Care November 2007	Patient Advocates Want Part D Changes A Medicare-administered drug benefit would be more affordable and comprehensive than the current private insurance-run drug benefit, say patient advocate groups.
The Motley Fool January 22, 2007 Michael P. Cecil	Will Medicare Negotiate With Drug Companies? One of the bedrock principles of our economic system is that those buying more of a product receive a discount. Wouldn't empowering Medicare to save taxpayers' money be widely embraced as a great idea? But how would pharma investors see it?
The Motley Fool December 30, 2010 Brian Orelli	This NICE Deal Could Foreshadow 2011 Value-based pricing is coming. The only way to encourage lower drug costs is to get the end user to pay the cost directly.
The Motley Fool July 21, 2010 Brian Orelli	Biogen Looks Good Now, but What About Tomorrow? Biogen Idec saw revenue increase 11% and adjusted earnings per share jump almost 75%, which is all well and good, but the longer-term prospects for the company aren't nearly as impressive.
Managed Care December 2007 Martin Sipkoff	Large Plans Do Well Under Part D, But Premium Hikes Cloud Future Profits should increase over the next two years for plans that stay the course, but politics and rising premiums may affect long-term results.
The Motley Fool January 7, 2010 Brian Orelli	Pfizer Strides Farther Into Generics Pfizer's new look might be just what the doctor ordered.
The Motley Fool October 26, 2010 Seth Jayson	From Gross to Net at Gilead Sciences Here's the margin picture for Gilead Sciences over the past few years.
Salon.com September 8, 2000 Alan Berlow	Prescription politics What's the difference between the Bush and Gore health plans?
The Motley Fool April 13, 2010 Brian Orelli	Teva Gets Less Generic The generic-drug maker makes a major push into branded-drug development.
The Motley Fool September 20, 2007 Brian Orelli	Winners and Losers in Universal Health Care Here's a look at the companies that stand to win or lose if Hillary Rodham Clinton is elected -- and gets her three-pronged health-care reform plan through Congress.
The Motley Fool October 6, 2010 Rich Duprey	3M Retires From Insuring Its Retirees Company will change its retirement relationship with employees.
The Motley Fool November 30, 2010 Brian Orelli	A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist.
The Motley Fool June 30, 2010 Brian Orelli	Which Midsized Biotech Is the Best Buy? Biogen Idec, Amgen, or Gilead? Which of these biotechs has the most potential for growth?
The Motley Fool December 6, 2004 Brian Gorman	Pill-Popping Nation Americans are using more prescription drugs. Unfortunately for big pharma investors, pharmaceutical companies' benefits from these trends are tempered by other factors.
Pharmaceutical Executive January 1, 2006 Bill Shearer	Patient Assistant Programs and Medicare Part D About 2.5 million low-income seniors who participate in prescription access programs are eligible for drug coverage under Medicare Part D - but the programs are out of alignment.
The Motley Fool October 21, 2010 Seth Jayson	From Gross to Net at GlaxoSmithKline Here's the current margin snapshot for GlaxoSmithKline and some of its sector and industry peers and direct competitors.
The Motley Fool January 25, 2011 Brian Orelli	2 Keys to Amgen's Continued Success Prolia and Xgeva have to perform.